Nirsevimab Shows Promise in Protecting Infants from RSV Lower Respiratory Tract Disease
A new study confirms that nirsevimab provides strong protection for infants against RSV-related lower respiratory tract disease, significantly reducing hospitalizations and healthcare visits during the RSV season.
Recent research published in the journal Pediatrics confirms that nirsevimab is highly effective in safeguarding infants against respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD). The study, led by Dr. Amber Hsiao from the Kaiser Permanente Vaccine Study Center in Oakland, California, analyzed data from the 2023-2024 RSV season involving nearly 32,000 infants.
The research demonstrated that nearly half of these infants received nirsevimab, and among them, the incidence of RSV LRTD was significantly lower. Specifically, nirsevimab showed an effectiveness rate of 87.2% against RSV LRTD, 98% in preventing hospitalizations due to RSV LRTD, and 71% against PCR-confirmed RSV infections. Infants who received the medication experienced fewer healthcare encounters related to RSV and had substantially reduced odds of hospitalization.
These findings bolster the recommendations by the Advisory Committee on Immunization Practices, advocating for infants under 8 months to receive nirsevimab at the start of their first RSV season. The study underscores the potential of nirsevimab as a critical tool in reducing the burden of RSV illness in young children, providing further evidence of its role in pediatric preventive care.
For more details, the full study can be accessed through the DOI: 10.1542/peds.2024-069510.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Genetic Study Reveals Breast Cancer Risk Factors in African Women
A pioneering study identifies unique genetic variants linked to breast cancer risk in African women, emphasizing the importance of inclusive genomic research for targeted prevention and treatment.
New Insights into Neuroblastoma Resistance: The Role of Oncogene Location and Dormant Tumor Cells
Recent breakthroughs reveal how the placement of the MYCN oncogene on extrachromosomal DNA rings drives neuroblastoma cell dormancy and therapy resistance, opening new avenues for targeted treatments.
Green-Mediterranean Diet Linked to Slowing Brain Aging
A green-Mediterranean diet including green tea and Mankai may help slow down brain aging, potentially preserving cognitive health over time. Learn about this groundbreaking study and its implications for healthy aging.
How Exercise Intensity Affects Your Gut Microbiome
Recent research shows that the intensity of exercise can impact gut microbiome health, influencing athletes' performance and well-being. Discover how training load and diet affect gut bacteria in this comprehensive overview.